Antimicrobial topical agents used in the vagina

Current Problems in Dermatology

Volumn 40, Issue , 2011, Pages 36-47

  Frey Tirri, Brigitte ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BORIC ACID; BUTOCONAZOLE; CLINDAMYCIN; CLOTRIMAZOLE; DEQUALINIUM; ECONAZOLE; ESTRADIOL; FENTICONAZOLE; FLUCONAZOLE; HEXETIDINE; IMIDAZOLE; IMIQUIMOD; METRONIDAZOLE; MICONAZOLE; NITROIMIDAZOLE; NYSTATIN; PODOPHYLLOTOXIN; PYRROLE; TERCONAZOLE; TIOCONAZOLE; TRIAZOLE; TRICHLOROACETIC ACID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACTINIC KERATOSIS; ALCOHOL CONSUMPTION; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BALANITIS; BEDTIME DOSAGE; BURNING SENSATION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CLINICAL PRACTICE; CONDYLOMA ACUMINATUM; CREAM; CRYOTHERAPY; DESQUAMATIVE VAGINITIS; DRUG EFFICACY; DRUG SAFETY; GARDNERELLA INFECTION; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; NONHUMAN; PATIENT COMPLIANCE; PREGNANCY; PRIORITY JOURNAL; PRURITUS; SEXUALITY; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; SUPPOSITORY; TREATMENT DURATION; TREATMENT FAILURE; TRICHOMONIASIS; VAGINA; VAGINA SECRETION; VAGINITIS; VULVOVAGINITIS;

ADMINISTRATION, INTRAVAGINAL; AMINOQUINOLINES; ANTI-INFECTIVE AGENTS, LOCAL; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; AZOLES; CLINDAMYCIN; DEQUALINIUM; FEMALE; HEXETIDINE; HUMANS; METRONIDAZOLE; NYSTATIN; PODOPHYLLOTOXIN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TRICHLOROACETIC ACID; VAGINITIS;

EID: 79951709246     PISSN: 14215721     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000321047     Document Type: Article

References (37)

1. Borin MT, Powley GW, Tackwell KR, Batts DH: Absorption of clindamycin after intravaginal application of clin-damycin phosphate 2% cream. J Antimi-crob Chemother 1995;35:833-841.
2. Sobel J, Peipert JF, McGregor A, et al: Efficacy of clindamycin vaginal ovule (3-day treatment) vs clindamycin vagi-nal cream (7-day treatment) in bacterial vaginosis. Infect Dis Obstet Gynecol 2001;9:9-15. (Pubitemid 32510019)
3. Ledger WL, Witkin SS: Vulvovaginal Infections. London, Manson Publishing, 2007.
4. Donders GGG, Vereecken A, Bosmans E, et al: Definition of a type of abnormal vaginal flora that is distinct from bacte-rial vaginosis: aerobic vaginitis. Br J Obstet Gynaecol 2002;109:1-10.
5. Boris J, Pahlson C, Larsson PG: Six years observation after successful treatment of bacterial vaginosis. Infect Dis Obstet Gynecol 1997;5:297-302. (Pubitemid 28079670)
6. Leaman D, Sobel J: Suppressive mainte-nance therapy of recurrent bacterial vag-inosis utilizing 0.75% metronidazole vaginal gel (abstract 010). Int J Gynecol Obstet 1999;67:S41.
7. Senok AC, Verstraelen H, Temmerman M, Botta GA: Probiotics for the treat-ment of bacterial vaginosis (review). Cochrane Database Syst Rev 2009;4:CD006289.
8. Raz R, Stamm WE: A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infection. N Engl J Med 1993;329:753-756. (Pubitemid 23262529)
9. Donders GGG: Management of genital infections in pregnant women. Curr Opin Infect Dis 2006;19:55-61.
10. Center for Disease Control and Prevention: 2006 Guidelines and treatment of sexually transmitted diseases. NMWR Recomm Rep 2006;55:1-94.
11. Leitich H: Antibiotika in der Schwanger-schaft. Ther Umsch 2005;62:13-16.
12. Brandt M, Hoyme UB, May TM, Lohm-ann K: Metronidazole administered intravaginally vs orally in treatment of bacterial vaginosis followed by prophy-laxis of recurrence with lactic acid i. vag.-a prospective randomized double-blind placebo-controlled multicenter study. Congr Infect Dis Soc Obstet Gynecol, Monterey August 2006.
13. Lugo-Miro VI, Green M, Mazur L: Com-parison of different metronidazole ther-apeutic regimens for bacterial vaginosis: a meta-analysis. JAMA 1992;268:92-95.
14. Martius J, Hoyme UB: Bakterielle Vagi-nose in Gynäkologie und Geburtshilfe. Guidelines of the German Association for Gynecology and Obstetrics, 2006.
15. Oduyebo OO, Anorlu RI, Ogunsola FT: The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women (review). Cochrane Database Syst Rev 2009;3:CD006055.
16. McDonald HM, Brocklehurst P, Gordon A: Antibiotics for treating bacterial vagi-nosis in pregnancy (review). Cochrane Database Syst Rev 2007;1:CD000262.
17. Brauss FW, Rioht H: Wirksamkeit von Dekamethylenaminochinaldiniumchlo-rid gegenüber pathogenen Mikroorgan-ismen. Münch Med Wochenschr 1974;35:1519-1520.
18. Peterson EE: Fluomizin vaginal tablets 10 mg dequalinium chloride. Medinova Ltd., 2006.
19. Della Casa V Noll H, Gonser S, Grob P, Graf F, Pohling G: Antimicrobial activity of dequalinium chloride against leading germs of vaginal infections. Arzneimit-telforschung/Drug Res 2002;52:699-705.
20. Weissenbacher ER, Flumozin study group: Comparative study of the efficacy of 10 mg dequalinium chloride in the local treatment of bacterial vaginosis. In press.
21. Hitschold T, Berle P: The antibacterial effectiveness of hexetidine vaginal tab-lets on pathogen flora of the cervix and vagina. Zentralblatt für Gynäkologie 1992;114:296-300.
22. Singh S, Sobel JD, Bhargava P, et al: Vagi-nits due to C. krusei: epidemiology, clinical aspects, and therapy. Clin Infect Dis 2002;35:1066-1070. (Pubitemid 35239466)
23. Sobel JD, Chaim W, Nagappan V, et al: Treatment of vaginitis caused by Can-dida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003;189:1297-1300. (Pubitemid 37542161)
24. Spinillo A, Zara F, Gardella B, et al: The effect of vaginal candidiasis on the shed-ding of human immunodeficiency virus in cervicovaginal secretions. Am J Obstet Gynecol 2005;192:774-779. (Pubitemid 40311269)
25. Wang CC, McClelland RS, Reilly M, et al: The effect of treatment of vaginal infec-tions on shedding of human immunode-ficiency virus type 1. J Infect Dis 2001; 183:1017-1022. (Pubitemid 32230948)
26. Nørgaard M, Pedersen L, Gislum M, Erichsen R, Søgaard KK, Schønheyder HC, Sørensen HT: Maternal use of flu-conazole and risk of congenital malfor-mations: a Danish population-based cohort study. J Antimicrob Chemother 2008;62:172-176. (Pubitemid 351865893)
27. Hengge UR, Ruczcka T: Topical immu-nomodulation in dermatology: potential of Toll-like receptor agonists. Dermatol Surg 2004;30:1101-1112. (Pubitemid 39120673)
28. Kaspari M, Gutzmer R, et al: Application of imiquimod by suppositories (anal tampons) efficiently prevents recur-rences after ablation of anal canal con-dyloma. Br J Dermatol 2002;147:757-759. (Pubitemid 35286164)
29. Buck HW, Guth KJ: Treatment of vaginal intraepithelial neoplasia (primarily low grade) with imiquimod 5% cream. J Low Genit Tract Dis 2003;7:290-293. (Pubitemid 37336602)
30. Hengge UR, Cusini M: Topical immuno-modulators for the treatment of external genital warts, cutaneous warts and mol-luscum contagiosum. Br J Dermatol 2003;149(suppl 66):15-19. (Pubitemid 38064508)
31. Van Seters M, van Beurden M, et al: Treatment of vulvar intraeptihelial neo-plasia with topical imiquimod. N Engl J Med 2008;358:1465-1473. (Pubitemid 351482738)
32. Krishna S: Comparison of podophyllo-toxin and imiquimod as anal condyloma acuminata therapy Dermatol Online J 2008;14:8.
33. Hengge UR: HPV-Infektion und Hauttu-more-Diagnostik und Therapie, ed 2. Stuttgart, Thieme, 2008.
34. Yan J, Chen SL, Wang HN, Wu TX: Meta-analysis of 5% imiquimod and 0.5% podophyllotoxin in the treatment of con-dylomata acuminata. Dermatology 2006;213:218-223. (Pubitemid 44567832)
35. Carrasco D, van der Straten M, Tyring SK: Treatment of anogenital warts with imiquimod 5% cream followed by surgi-cal resection of residual lesions. J Am Acad Dermatol 2002;47:212-216.
36. Gross G, Tyring SK, von Krogh G, Barasso R: External genitalia: treatment; in Gross G, Barasso R (eds): Human Papillomavirus Infection: A Clinical Atlas. Berlin, Ullstein Mosby 1997, pp 365-376.
37. Godely MJ, Bradbeer CS, Gellan M, Thin RN: Cryotherapy compared with trichlo-roacetic acid in treating genital warts. Genitourin Med 1987;63:390-392. (Pubitemid 18026260)